Evaluation of 64Cu- and 125I-radiolabeled bitistatin as potential agents for targeting alphavbeta3 integrins in tumor angiogenesis

The formation of new blood vessels (angiogenesis) is a feature common to all solid tumors. The integrin receptor alpha v beta 3, which is found on endothelial cells lining newly growing blood vessels at a higher density than on mature blood vessels, is being explored as a marker for tumor angiogenes...

Full description

Saved in:
Bibliographic Details
Published in:Bioconjugate chemistry 2004-09, Vol.15 (5), p.988
Main Authors: McQuade, Paul, Knight, Linda C, Welch, Michael J
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The formation of new blood vessels (angiogenesis) is a feature common to all solid tumors. The integrin receptor alpha v beta 3, which is found on endothelial cells lining newly growing blood vessels at a higher density than on mature blood vessels, is being explored as a marker for tumor angiogenesis. Bitistatin, a member of the disintegrin family of polypeptides, has affinity for alpha v beta 3 integrins. To determine whether radiolabeled bitistatin could target tumors, its biodistribution was tested in tumor-bearing mice. For initial validation studies, 125I-bitistatin was injected into BALB/c mice bearing EMT-6 mouse mammary carcinoma tumors, a model that is highly vascular but which lacks alpha v beta 3 directly on tumor cells. Tumor uptake reached maximal values (11.7 plus or minus 4.6 %ID/g) at 2 h. Co-injection of 200 mu g of unlabeled bitistatin reduced tumor uptake 62%, suggesting that the binding of 125I-bitistatin is receptor-mediated. This work was extended to include the beta+-emitting radionuclide 64Cu, which was attached to bitistatin via 1,4,7,10-tetraazacyclododecane-N,N',N"IN"'-tetraacetic acid (DOTA). This modification did not significantly alter receptor binding in vitro. MicroPET images obtained with 64Cu-DOTA-bitistatin showed that the tumor could easily be identified 4 h after administering the radiopharmaceutical. The biodistribution of 64Cu-DOTA-bitistatin differed from the 125I analogue, in that maximum tumor uptake was nearly 8-fold lower and took at least 6 h to reach maximal binding (1.6 plus or minus 0.2 %ID/g). As with 125I-labeled bitistatin, the 64Cu conjugate showed a 50% reduction in tumor uptake with the co-injection of 200 mu g of unlabeled bitistatin (0.8 plus or minus 0.2 %ID/g). Competition studies with integrin-specific peptides indicated that the tumor uptake was related to both alpha v beta 3 and alpha Iib beta 3 integrin binding. To see if tumor uptake could be improved upon, 64Cu was tethered to bitistatin using bromoacetamidobenzyl-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (BAD). Tumor uptake for 64Cu-BAD-2IT-bitistatin was higher than the DOTA conjugate at all time points, reaching a maximum at least 6 h postinjection (5.2 plus or minus 0.6 %ID/g); however, this was accompanied by higher uptake in nontarget organs at all time points. Radiolabeled ligands of this type may be useful in the targeting of tumor angiogenesis, but the choice of radiolabeling approach has a significant impact on the
ISSN:1043-1802
1520-4812